M emory and effector CD8
ϩ T cells play an important role in viral eradication through their ability to produce various factors involved in suppression of viral replication (1-3) as well as in cytolysis of virus-infected cells (4, 5) . Studies of human memory CD8 ϩ T cells are important for vaccine development because identification of a vaccine that can effectively induce memory T cells is expected to prevent infection by various pathogens, including viruses, bacteria, and parasites. However, despite their clinical importance, the characteristics and differentiation of memory CD8 ϩ T cells remain unclear in both human and mouse.
CD27 and CD28 can be used as cell surface markers to discriminate naive and memory CD8 ϩ T cells from effector CD8 ϩ T cells (6 -8) . These molecules are well known as T cell costimulatory molecules. CD28 interacts with CD80(B7-1) and CD86(B7-2), which are expressed on APCs (9, 10) , and has a dual role as an adhesion and a signaling molecule. Coengagement of CD28 with the TCR is required for T cell activation (11) . CD28 is downregulated after TCR stimulation (12) . CD27 is less well characterized than CD28. Its expression is up-regulated upon TCR stimulation (13) (14) (15) . The CD27 ligand CD70 is transiently up-regulated by Ag receptor stimulation on both T and B cells (16) . CD27 ligation enhances TCR-induced expansion of both CD4 ϩ and CD8 ϩ T cells (17) (18) . A recent study suggested that CD27 is required for generation of T cell memory rather than for differentiation of CD8 ϩ T cells to effector cytotoxic T cells (19) . CD45RA, which is one of two CD45 isoforms, can be also used as a marker of naive CD8 ϩ T cells (20) . Recent studies using virus epitope-specific HLA tetramers demonstrated that CD45RA ϩ
CD8
ϩ T cells include effector T cells (21, 22) , suggesting that naive CD8 ϩ T cells cannot be identified by the presence of CD45RA alone.
Previous studies using human CD8 ϩ T cells costained with an anti-CD45RA mAb and an anti-CD27 or anti-CD28 showed that CD8 ϩ T cells with a CD28 ϩ CD45RA Ϫ or CD27 ϩ CD45RA Ϫ phenotype express no or only a low level of perforin but have the ability to produce cytokines, while CD8 ϩ T cells with a CD28 Ϫ CD45RA ϩ or CD27 Ϫ CD45RA ϩ phenotype express a high level of perforin but have a limited ability to produce cytokines (8, 23) . These observations strongly suggest that human CD8 ϩ T cells with a CD28 ϩ CD45RA Ϫ or CD27 ϩ CD45RA Ϫ phenotype are memory cells and that those with a CD28 Ϫ CD45RA ϩ or CD27 Ϫ D45RA ϩ phenotype are effector cells. As CD8 ϩ T cells with a CD28
Ϫ CD45RA Ϫ or CD27 Ϫ CD45RA Ϫ phenotype express a medium level of perforin, these cells are thought to be intermediate between memory and effector T cells, i.e., to be memory/ effector T cells (23, 24) .
CCR7 is a chemokine receptor that functions as a homing receptor in the migration of naive and memory CD8 ϩ T cells to secondary lymphoid tissues. A role for CCR7 in CD8
ϩ T cells has been demonstrated through the identification of CCR7
CD45RA
ϩ naive CD8 ϩ T cells and CCR7 ϩ CD45RA Ϫ and CCR7 Ϫ CD45RA Ϫ memory CD8 ϩ T cells (25) . Furthermore, a recent study suggested the following differentiation lineage for Agspecific CD8 ϩ T cells: 
CD8
ϩ T cells are preterminally differentiated and terminally differentiated cells, respectively. Thus, analysis of chemokine receptor expression may be useful for discriminating among naive, memory, and effector CD8 ϩ T cells. In this study, we attempted to clarify the differentiation pathway of memory CD8 ϩ T cells to memory/effector CD8 ϩ T cells. We used HLA class I tetramers and flow cytometry to detect EBV-or human CMV (HCMV) 4 -specific CD8 ϩ T cells in healthy individuals. Tetramer ϩ CD8 ϩ T cells were analyzed for CD27, CD28, CD45RA, and perforin expression by four-color flow cytometric analysis. In addition, the surface expression of two chemokine receptors, CCR5 and CCR7, and the function (cytotoxic activity and cytokine production) of different CD27/CD28 subsets of CD45RA Ϫ CD8 ϩ T cells were examined. These analyses enabled us to propose a pathway for the differentiation of memory CD8 ϩ T cells to memory/effector CD8 ϩ T cells.
Materials and Methods

Blood samples
Blood samples were taken from 18 HCMV-seropositive and EBV-seropositive healthy adult individuals (see Table II ).
Peptides
The HLA-A*0201-restricted HCMV-specific CTL epitope pp65 495-503 (NLVPMVATV; HCMV-1) (27) and two HLA-A*1101-restricted EBVspecific CTL epitopes, EBV-1 (EBV 3B 416 -424; IVTDFSVIK) and EBV-2 (EBV 3B 399 -408; AVFDRKSDAK) (28), were previously identified. These peptides were generated using an automated peptide synthesizer (model PSSM-8; Shimazu, Kyoto, Japan) with F-moc strategy followed by cleavage. The purity of the synthesized peptides was examined by mass spectrometry.
Cells
C1R cells expressing HLA-A*1101 (C1R-A*1101) or HLA-A*0201 (C1R-A*0201) were previously generated (29) and were maintained in RPMI 1640 medium supplemented with 10% FCS and 0.15 mg/ml hygromycin B.
Monoclonal Abs
Anti-CD27-FITC mAb, anti-CD28-FITC mAb, anti-CD28-PE mAb, anti-CD28-CyChrome mAb, anti-CD28-allophycocyanin mAb, anti-CD45RA-CyChrome mAb, anti-CCR5-FITC mAb, anti-CCR7 mAb, and antiperforin-PE mAb were obtained from BD PharMingen (San Diego, CA). Anti-CD8-FITC mAb and anti-CD8-allophycocyanin mAb were obtained from DAKO (Glostrup, Denmark).
HLA class I/EBV or HCMV peptide tetramers
HLA class I-peptide tetrameric complexes were synthesized as previously described (30) . Briefly, recombinant HLA class I proteins (HLA-A*0201 and HLA-A*1101) and human ␤ 2 -microglobulin were produced in Escherichia coli cells transformed with the relevant expression plasmids. The H chain was modified by deletion of the transmembrane cytosolic tail and COOH-terminal addition of a sequence containing the BirA biotinylation site. Two EBV CTL epitopes (EBV-1 and EBV-2) and one HCMV CTL epitope (HCMV-1) were used for refolding of HLA class I molecules. The HLA class I-peptide complexes were refolded in vitro. The 45-kDa complexes were isolated using gel filtration on a Superdex G75 column (Amersham Pharmacia Biotech, Little Chalfont, U.K.). Purified complexes were biotinylated with BirA enzyme (Avidity, Denver, CO). The biotinylated complexes were purified using gel filtration first on a Superdex G75 column and then on a MonoQ column (Amersham Pharmacia Biotech). HLA class I/peptide tetrameric complexes (tetramers) were mixed with allophycocyanin-labeled streptavidin (BD PharMingen) at a molar ratio of 4:1.
Flow cytometric analysis
CD8 ϩ T cells were purified from cryopreserved or fresh PBMC using anti-CD8-coated magnetic beads (MACS CD8 Microbeads; Miltenyi Biotec, Bergisch Gladbach, Germany). The percentage of CD8 ϩ T cells in purified cells was Ͼ98%. A total of 1 ϫ 10 6 CD8 ϩ T cells were mixed with tetramers at a concentration of 0.02-0.04 mg/ml. After incubation at 37°C for 30 min, the cells were washed once with RPMI/10% FCS, and then anti-CD27 mAb, anti-CD28 mAb, and anti-CD45RA mAb were added to the cell suspension. The cells were incubated at 4°C for 30 min, and then the cells were washed two times with PBS/10% FCS.
To determine intracellular perforin expression in CD27/CD28 subsets of both tetramer-positive cells and total CD8 ϩ T cells, cells stained with anti-CD27 mAb, anti-CD28 mAb, and anti-CD45RA mAb were fixed with 4% paraformaldehyde at 4°C for 20 min, then permeabilized with PBS supplemented with 0.1% saponin containing 20% FCS (permeabilizing buffer) at 4°C for 10 min. Cells were washed with permeabilizing buffer and then resuspended in 100 l of the same buffer. Anti-perforin mAb was added, the cell suspension was incubated at 4°C for 30 min, and the cells were washed three times in permeabilizing buffer at 4°C. PE-labeled mouse IgG1 was used as negative control. The cells were finally resuspended in PBS containing 2% paraformaldehyde and then were analyzed using a FACSCalibur with CellQuest software (BD Biosciences, San Jose, CA). Between 70,000 and 200,000 gated events were acquired for analysis of intracellular perforin. Intracellular perforin expression is represented as the normalized mean fluorescence intensity (NMFI), which is the mean fluorescence intensity (MFI) of cellsstained with anti-perforin-PE mAb divided by the MFI of cells stained with the control mouse IgG1-PE mAb. Cr in saline and then washed three times with RPMI 1640 medium containing 10% NCS. Labeled target cells (2 ϫ 10 3 /well) were added into U-bottom 96-well plates with the indicated amount of peptide. After incubation for 1 h, CD8
CTL assay
ϩ T cells purified by anti-CD8 mAb-coated beads or CD27
ϩ T cells purified by a cell sorter (FACSVantage SE; BD Biosciences) were added and the mixtures were incubated for 6 h at 37°C. The supernatants were collected and analyzed with a gamma counter. FIGURE 1. CD28/CD45RA phenotype of EBV-specific CD8 ϩ T cells. PBMCs from individuals M14 (A) and U5 (B) were stained simultaneously with the EBV-1-A*1101 tetramer, anti-CD8 mAb, anti-CD28 mAb, and anti-CD45RA mAb. Similarly, PBMCs from individuals M14 (C) and A21 (D) were simultaneously stained with the EBV-2-A*1101 tetramer, anti-CD8 mAb, anti-CD28 mAb, and anti-CD45RA mAb. Tetramer ϩ CD8 ϩ T cells were gated and then analyzed for CD28 and CD45RA expression Cr release was determined by measuring the cpm in supernatants from wells containing only target cells (cpm spn). Maximum 51 Cr release was determined by measuring the cpm in supernatants from wells containing target cells in the presence of 2.5% Triton X-100 (cpm max). Specific lysis ϭ ((cpm exp Ϫ cpm spn)/(cpm max Ϫ cpm spn)) ϫ 100, where cpm exp is the cpm in supernatants of wells containing both target and effector cells.
Measurement of cytokine-producing cells by flow cytometry
To measure cytokine production in CD27/CD28 subsets of EBV-or HCMV-specific CD8 ϩ T cells, cells were purified from fresh PBMC isolated from healthy individuals who have EBV-or HCMV-specific CD8 ϩ T cells using anti-CD8-coated magnetic beads (MACS CD8 Microbeads; Miltenyi Biotec). CD8 ϩ T cells (2 ϫ 10 6 ) were dispensed into a U-bottom 96-well plate with or without 1 M of a EBV or HCMV peptide and incubated for 6 h. After the first 2 h of incubation, brefeldin A (10 g/ml) was added to each well. The cells were then stained with a mixture of anti-CD27 mAb, anti-CD28 mAb, and anti-CD45RA mAb, fixed with 4% paraformaldehyde at 4°C for 20 min, and then permeabilized with PBS supplemented with 0.1% saponin containing 20% NCS (permeabilizing buffer) at 4°C for 10 min. Cells were resuspended in permeabilizing buffer and then stained with anti-IFN-␥ mAb, anti-TNF-␣ mAb, or antimacrophage-inflammatory protein (MIP)-1␤ mAb. The cells were finally resuspended in PBS containing 2% paraformaldehyde and then the percentage of intracellular IFN-␥-, MIP-1␤-, or TNF-␣-positive cells was analyzed by flow cytometry. To measure the number of EBV-or HCMVspecific CD8
ϩ T cells in each CD27/CD28 subset, CD8 ϩ T cells were stained with an EBV or HCMV tetramer and a mixture of anti-CD27 mAb, anti-CD28 mAb, and anti-CD45RA mAb. The percentage of cytokine-positive cells in tetramer-positive cells in each CD27/CD28 subset was determined.
Results
Predominant existence of the CD28
ϩ CD45RA Ϫ subset in EBV- specific CD8 ϩ T
cells from healthy individuals
HLA-A*1101 is a common allele in the Japanese population, and IVTDFSVIK (EBV-1) and AVFDRKSDAK (EBV-2) are known to be HLA-A*1101-restricted immunodominant epitopes. Therefore, we used these peptides to generate tetramers to analyze EBVspecific CD8 ϩ T cells in PBMC from EBV-seropositive healthy Japanese individuals with HLA-A*1101. Ex vivo flow cytometry analysis demonstrated that in 5 of the 10 individuals studied Ͼ0.1% of total CD8 ϩ T cells were EBV-1 tetramer ϩ , and that in 6 of the 10 individuals Ͼ0.1% of total CD8 ϩ T cells were EBV-2 tetramer ϩ (Table I) . Eight individuals had tetramer ϩ CD8 ϩ T cells for at least one of the EBV epitopes. Analysis of CD28 and CD45RA expression on the tetramer ϩ CD8 ϩ T cells demonstrated Ϫ CD8 ϩ T cells. The CD8 ϩ T cells were stained simultaneously with the EBV-1-A*1101 tetramers (M10 and M19) or HCMV-1-A*0201 tetramer (M30), and anti-CD27, anti-CD28 mAb, and anti-perforin mAb or mouse IgG1 mAb. Perforin expression in each CD27/CD28 subset of tetramer ϩ CD45RA Ϫ CD8 ϩ T cells is represented as the NMFI, i.e., the MFI of cells stained with anti-perforin-PE mAb divided by the MFI of cells stained with mouse IgG1-PE mAb. ϩ T cells. We also attempted to detect HCMV-specific CD8 ϩ T cells in PBMC from HCMV-seropositive healthy individuals with HLA-A2 using an HLA-A*0201 tetramer containing the HCMV epitope, pp65 495-503 (NLVPMVATV; HCMV-1). More than FIGURE 4. Cytotoxic activity of HCMV-1-specific and EBV-specific CD8 ϩ T cells. A, Cytotoxic activity of EBV-specific CD8 ϩ T cells. CD8 ϩ T cells were isolated from two individuals, U5 and E1. The percentage of HLA-A*1101-restricted, EBV-specific CD8 ϩ T cells was measured using EBV-1-A*1101 and EBV-2-A*1101 tetramers. The relative cytotoxic activity of the separated CD8 ϩ T cells for C1R-A*1101 cells pulsed with EBV-1 and EBV-2 peptides (F) was measured at different effector (tetramer ϩ cells):target ratios. The relative cytotoxic activity of these cells for C1R cells pulsed with EBV-1 and EBV-2 peptides (‚) and HLA-A*1101-restricted, EBV-1-specific CTL lines for C1R-A*1101 cells pulsed with EBV-1 and EBV-2 peptides (E) was measured at an effector (tetramer ϩ cells):target ratio of 1:1. B, Cytotoxic activity of two CD27/CD28 subsets of HCMV-specific CD45RA Fig. 2A and Table II) . Exceptions were observed in three of the 18 individuals (A16, U2, and U9), where the CD27 Ϫ CD28 Ϫ subset was the major population (Table II) . Perforin expression was lowest in the CD27 ϩ CD28 ϩ subset, highest in the CD27 Ϫ CD28 Ϫ subset, and intermediate in the CD27 ϩ CD28 Ϫ and the CD27 Ϫ CD28 ϩ subsets (Fig. 2B ). This suggests that CD27 ϩ CD28 ϩ CD45RA Ϫ CD8 ϩ cells are memory T cells and that this subset may differentiate via the CD27 ϩ CD28 Ϫ subset and/or the CD27 Ϫ CD28 ϩ subset to the CD27 Ϫ CD28 Ϫ subset, which from its perforin expression level appears to have characteristics more typical of cytotoxic effector T cells than the other subsets.
CD27/CD28 SUBSETS OF CD45RA
To further investigate CD27/CD28 subsets in virus-specific CD45RA Ϫ CD8 ϩ T cells, we examined CD8 ϩ T cells from indi- (Table I) Ϫ CD28 ϩ cells in EBV-specific CD8 ϩ T cells was much lower than that in total CD8 ϩ T cells (Fig. 3A) . Similarly, CD27 ϩ CD28 ϩ , CD27 ϩ CD28 Ϫ , and CD27 Ϫ CD28 Ϫ subsets were observed in HCMV-specific CD8 ϩ T cells from individual M30, while only a small number of CD27 Ϫ CD28 ϩ cells was detected (Fig. 3A) . Perforin expression in each EBV-specific and HCMV-specific CD45RA
Ϫ CD8 ϩ T cell subset was similar to that observed in each total CD45RA
Ϫ CD8 ϩ T cell subset, although expression in the CD27 ϩ CD28 Ϫ subset appeared to be higher in EBV-and HCMV-specific CD8 ϩ T cells than in total CD8 ϩ T cells (Figs. 2B and 3B ). These results support the idea that the CD27 ϩ CD28 ϩ and CD27 Ϫ CD28 Ϫ subsets are memory and memory/effector CD8 ϩ T cells, respectively, and that the CD27 ϩ CD28 Ϫ subset is an intermediate in the differentiation pathway from CD27 ϩ CD28 ϩ to CD27 Ϫ CD28 Ϫ .
Cytotoxic activity of different CD27/CD28 subsets of
We evaluated the ex vivo cytotoxic activity of EBV-specific
cells with different CD27/CD28 phenotypes for target cells (C1R-A*1101 or autologous T cell blast) pulsed with EBV-1 or EBV-2. CD8
ϩ T cells were isolated from PBMCs from two EBV-seropositive, healthy individuals (E1 and U5) with HLA-A*1101. Approximately 98 and 81% of EBV-specific CD8 ϩ T cells from E1 and U5, respectively, had a CD27 ϩ CD28 ϩ CD45RA Ϫ phenotype (Tables I and II) . These CD8 ϩ T cells exhibited no cytotoxic activity for HLA-A*1101 ϩ target cells pulsed with EBV-1 and EBV-2 peptides at a tetramer ϩ CD8 ϩ T cell:target ratio of 1:1 (Fig. 4A) . These results indicate that CD27 ϩ CD28 ϩ CD45RA Ϫ CD8 ϩ T cells are not effector cytotoxic T cells.
To clarify the cytotoxic activity of the CD27 ϩ CD28 Ϫ and CD27 Ϫ CD28 Ϫ subsets of CD45RA Ϫ CD8 ϩ T cells, we sorted these cells from PBMCs isolated from healthy individuals. We FIGURE 5. Cytokine production by CD27/CD28 subsets of EBV-or HCMV-specific CD8 ϩ T cells. CD8 ϩ T cells were isolated from fresh PBMC from individual M19, who has EBV-1-specific CD8 ϩ T cells, and individual U2, who has HCMV-1-specific CD8 ϩ T cells. CD8 ϩ T cells from M19 and U2 were stimulated with EBV-1-specific and HCMV-specific peptides, respectively. Cells producing cytokines in different CD27/CD28 subsets were analyzed by flow cytometry. The number of EBV-specific and HCMV-specific CD8 ϩ T cells was measured using EBV-1 tetramers and the HCMV-1 tetramer, respectively. The percentage of cytokine-producing cells in CD27/CD28 subsets of EBV-specific and HCMV-specific CD8 ϩ T cells was calculated.
used PBMCs isolated from individual M30, whose HCMV-specific CD45RA Ϫ CD8 ϩ T cells contained both subsets (Fig. 3A) , because PBMCs containing both EBV-specific CD8 ϩ T cell subsets were not available for this experiment. Both the CD27 ϩ CD28 Ϫ and CD27 Ϫ CD28 Ϫ subsets effectively killed target cells pulsed with an HCMV-1 peptide (Fig. 4B) . These results are consistent with the perforin expression levels observed in these subsets.
Cytokine production in different CD27/CD28 subsets of
Cytokine production in CD27 ϩ CD28 ϩ , CD27 ϩ CD28 Ϫ , and CD27 Ϫ CD28 Ϫ subsets of CD45RA Ϫ CD8 ϩ T cells was investigated using two EBV epitope peptides and an HCMV-1 peptide. Purified CD8 ϩ T cells from individuals U2 and M19 were analyzed for IFN-␥-, TNF-␣-, and MIP-1␤-producing cells 6 h after 
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CD27/CD28 SUBSETS OF CD45RA Ϫ CD8 ϩ T cells stimulation with the appropriate peptide(s). All three subsets from both individuals effectively produced these three cytokines, although cytokine-producing cells seemed to be more prevalent in the CD27 Ϫ CD28 Ϫ subset than in other subsets (Fig. 5) . These results indicate that these three subsets of HCMV-specific and EBV-specific CD8 ϩ T cells are able to effectively produce cytokines.
CCR5 expression in different CD27/CD28 subsets of
Our recent study showed that CD28 ϩ CD45RA Ϫ CD8 ϩ T cells express a high level of CCR5, and that this expression is decreased in CD28
Ϫ CD45RA Ϫ CD8 ϩ T cells (31) . To further investigate CCR5 expression in different CD27/CD28 subsets of CD45RA Ϫ CD8 ϩ T cells, we stained total CD8 ϩ T cells from three individuals (M10, M19, and M30) with anti-CCR5, anti-CD27, anti-CD28, and anti-CD45RA mAb (Fig. 6) (Fig. 6) , suggesting that this subset may have characteristics more similar to memory T cells.
To clarify CCR5 expression in these subsets in EBV-and HCMV-specific CD8 T cells, we stained CD8 ϩ T cells purified from three HLA-A*1101 ϩ or HLA-A*0201 ϩ individuals (M10, M19, and M30), in whom most tetramer ϩ CD8 ϩ T cells were CD45RA Ϫ (Table I) , with tetramers and anti-CD27, anti-CD28, and anti-CCR5 mAbs. CCR5 expression was similar to that observed in total CD8 ϩ T cells, although the percentage of CCR5 ϩ cells in each subset was higher in tetramer ϩ CD8 ϩ T cells than in total CD8 ϩ T cells (Fig. 7) . These results indicate that the number of CCR5 ϩ cells decreased during differentiation from memory 
CD28
ϩ subset contains both CCR7 ϩ and CCR7 Ϫ populations (Fig. 8A) . In contrast, most cells in both the CD27 ϩ
Ϫ and CD27
Ϫ
CD28
Ϫ subsets were CCR7 Ϫ . These results, together with those of CCR5 expression in these subsets of CD45RA
Similar results were observed in the CD27
ϩ CD28 ϩ subset of EBV-specific CD45RA Ϫ CD8 ϩ T cells from two individuals, although the percentage of CCR7 ϩ cells differed between the two (Fig. 8B) . A higher number of CCR7 ϩ cells was observed in individual M10 compared with M19, suggesting that the CD27 ϩ CD28 ϩ subset of EBV-specific CD8 ϩ T cells is more differentiated in individual M19 than M10. Only 10 -15% of
Ϫ , while ϳ30% of tetramer ϩ CD8 ϩ T cells in M19 expressed these phenotypes (Figs. 3, 7A , and 8B), also suggesting that EBV-specific CD8 ϩ T cells are more differentiated in M19 than in M10.
The CD27
Ϫ CD28 ϩ subset does not express CCR7 (Fig. 8A) , while most of this subset expresses CCR5 (Fig. 7) . This suggests that this subset is more differentiated than CD27 Ϫ CD8 ϩ T cells seems to vary among individuals. The level of perforin expression in the CD27 ϩ CD28 Ϫ subset was similar to that of the CD27 Ϫ CD28 Ϫ subset in individual U2, but similar to that of the CD27 ϩ CD28 ϩ subset in individuals U5, U7, U10, and U11 (Fig. 2) . Similar findings were observed in EBVspecific CD8 ϩ T cells. The CD27 ϩ CD28 Ϫ subset of EBV-specific CD8 ϩ T cells from individual M19 expressed a lower level of perforin than the same subset from individual M30 (Fig. 3) . As the sorted CD27 ϩ CD28 Ϫ subset of HCMV-specific CD8 ϩ T cells from M30, which expressed a relatively higher level of perforin, effectively killed target cells, this subset should include effector cytotoxic T cells. A recent study also showed that the CD27 ϩ CD28 Ϫ CD45RO ϩ subset of EBV-specific CD8 ϩ T cells has cytotoxic activity (33) . Thus, it is likely that this subset contains memory/effector CD8 ϩ T cells which can kill target cells but may include a wide range of subpopulations between memory and memory/effector phenotypes or various combinations of memory and memory/effector cells in different individuals.
Discussion
A previous study showed that CD27 ϩ CD45RA Ϫ CD8 ϩ and CD27 Ϫ CD45RA Ϫ CD8 ϩ T cells effectively produce IFN-␥ and TNF-␣ after strong and nonspecific stimulation with PMA and ionomycin (8) . Recent studies showed effective production of IFN-␥ from both CD28 ϩ and CD28 Ϫ fractions and from both CD45RA ϩ and CD45RA Ϫ fractions in EBV-specific CD8 ϩ T cells after epitope peptide stimulation (34) . In addition, a recent study showed that perforin expression and cytokine production segregated into subpopulations of CD8 ϩ T cells: perforin-positive cells express CD45RA but neither CD27 nor CD28, while IFN-␥-producing cells have both CD28(CD27) ϩ and CD28(CD27) Ϫ phenotypes and a CD45RA Ϫ phenotype (35) . These studies imply that the CD27 ϩ CD28 ϩ , CD27 ϩ CD28 Ϫ , and CD27 Ϫ CD28 Ϫ subsets of CD45RA Ϫ CD8 ϩ T cells can effectively produce cytokines. Indeed, we showed in this work that these subsets effectively produced IFN-␥, TNF-␣, and MIP-1␤ after stimulation with epitope peptides. Thus, the CD27 ϩ CD28 Ϫ and CD27 Ϫ CD28 Ϫ subsets have cytotoxic activity and can produce cytokines, whereas the CD27 ϩ CD28 ϩ subset can only produce cytokines. Our recent study (31) Ϫ CD45RA ϩ effector CD8 ϩ T cell population (31) . Because CCR5 is a receptor for RANTES, MIP-1␣, and MIP-1␤ (36 -39) , it may play a role in the migration of memory CD8 ϩ T cells to secondary lymph nodes and inflammatory sites. Indeed, recent studies showed accumulation of CCR5
ϩ T cells at inflammatory sites in inflammatory kidney diseases (40) , inflammatory bowel diseases (41) , multiple sclerosis (42, 43) , and rheumatoid arthritis (44) . In contrast, binding of CCR5 ligands and CD3/CD28 costimulations causes down-regulation of CCR5 surface expression (45) (46) (47) . These findings suggest that some CCR5
ϩ T cells may stop expressing CCR5 following migration to inflammatory sites and recognition of epitopes presented by MHC molecules.
A recent study demonstrated that both the CD27 ϩ CD28 Ϫ and CD27 Ϫ CD28 Ϫ subsets of CD45RO ϩ CD8 ϩ T cells expand in acute EBV-infected individuals and that both subsets have cytotoxic activity (34) . This study also showed that, in a CD3 mAbmediated, redirected cytotoxicity assay, a CD27 ϩ CD28 ϩ CD45RO ϩ subset from a healthy individual had no cytotoxic activity while this subset from a patient with acute EBV infection had cytotoxic activity. The present study showed that this subset in EBV-specific CD8 ϩ T cells from EBV-seropositive healthy individuals showed low perforin expression and no cytotoxic activity (Figs. 3 and 4) . These findings suggest that this subset of EBVspecific CD8 ϩ T cells in patients with acute EBV infection may contain populations with cytotoxic effector function that are difficult to discriminate by analysis of CD27/CD28/CD45RA phenotypes. Previous studies have analyzed the expression of surface molecules on EBV-specific CD8 ϩ T cells from EBV-seropositive healthy individuals by flow cytometry using HLA class I tetramers and mAb against these molecules (48, 49) . These studies showed that these cells express CD27, CD28, CD45RO, and CD62L, although the percentage of EBV-specific CD8 ϩ T cells expressing these molecules varied among individuals. Using HLA-A*1101 latent epitope tetramers, the present study showed that most EBV-specific CD8 ϩ T cells from EBV-seropositive healthy individuals have a CD27 ϩ CD28 ϩ
FIGURE 9.
CD45RA
Ϫ memory phenotype. A recent study revealed that EBV lytic epitope-specific CD8 ϩ T cells heterogeneously express CD28 and CD45RA/RO, whereas most EBV latent epitope-specific CD8 ϩ T cells express CD28 and CD45RO (34) . This suggests that EBV latent epitope-specific CD8 ϩ T cells are memory T cells while EBV lytic epitope-specific CD8 ϩ T cells include both memory and memory/effector or effector T cells. The use of two HLA-A*1101 latent epitope tetramers in the present study also showed that ϳ80% of EBV-specific CD8 ϩ T cells express a (CD27 ϩ )CD28 ϩ CD45RA Ϫ memory phenotype in EBV-seropositive healthy individuals. However, this varied from 60 to 98% among individuals (Table I) . In summary, we investigated the expression of perforin and two chemokine receptors as well as the function (cytotoxicity and cytokine production) of CD27/CD28 subsets of CD45RA Ϫ CD8 ϩ T cells. The data suggested a differentiation pathway for memory CD8 ϩ T cells into memory/effector CD8 ϩ T cells. Further detailed analysis of each step in the differentiation pathway of memory CD8 ϩ T cells is important for our understanding of immune memory in CD8 ϩ T cells.
